Supreme Court asks DoJ for input on whistleblower evidence standards

The Department of Justice has rounded up billions of dollars from drugmakers in one whistleblower case after another. But some recent court decisions suggest that whistleblowers could face a higher bar for getting their cases heard. Now, as Pharmalot reports, the U.S. Supreme Court is asking the Solicitor General for its opinion on the subject.

The individual case in question pits whistleblower Noah Nathan against Takeda Pharmaceutical. Nathan, a Takeda sales manager, claims that the company pushed higher doses of its Kapidex stomach drug than the FDA had approved. A federal district court tossed out Nathan's claims, however, saying that his evidence wasn't specific enough, and the Fourth Circuit agreed.

Whistleblowers have to put forth details that "allege with particularity that specific false claims were presented to the government for payment," the court ruled (as quoted by Pharmalot). But the court also acknowledged that obtaining that sort of detail on individual health claims or prescription invoices can be stymied by privacy laws.

Nathan has asked the Supreme Court to hear the case, because the Fourth Circuit's opinion--shared by three other circuit courts--contradicts the views of four others, which share a broader view of sufficient evidence. And now that the court is back in session, it has asked for some input from the administration.

Given the Justice Department's dogged pursuit of drugmakers under the False Claims Act, we'd bet that prosecutors would prefer to deal with the lower standards. But we'll have to wait and see what the Solicitor General says--and what the Supreme Court does after that.

- read the Pharmalot piece

Special Report: Pharma's Top 11 Marketing Settlements

Relatled Articles:
Amgen whistleblower went undercover for the feds
FDA fraud-busting pilot program aims at pharma
Feds still zealous about off-label marketing, DoJ official says
Pharma tops off DoJ settlement ranking

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.